Stacy R. Lindborg, PhD, President and CEO of IMUNON, Inc, has nearly 30 years of pharmaceutical and biotechnology industry experience with a focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and innovative development platforms to increase productivity. Prior to IMUNON, she was Executive Vice President and Co-CEO at BrainStorm Cell Therapeutics. She previously was Vice President & Global Analytics and Data Sciences Head at Biogen and began her biopharmaceutical career at Eli Lilly.
Dr. Lindborg received an MA and PhD in statistics, and a BA in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.
New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial designs and the complexities of diseases such as certain cancers and rare disorders, which may lead to more efficient trials, lower development costs, and faster innovation.